Etiopathogenic Role of Surfactant Protein D in the Clinical and Immunological Expression of Primary Sjögren Syndrome

2014 ◽  
Vol 42 (1) ◽  
pp. 111-118 ◽  
Author(s):  
María José Soto-Cárdenas ◽  
Myriam Gandía ◽  
Pilar Brito-Zerón ◽  
Maria Teresa Arias ◽  
Noelia Armiger ◽  
...  
Keyword(s):  
Renal Involvement ◽  
Serum Levels ◽  
Surfactant Protein ◽  
Sjögren Syndrome ◽  
Surfactant Protein D ◽  
Sjogren Syndrome ◽  
Mean Values ◽  
Primary Sjögren Syndrome ◽  
Genotype 2

Objective.To analyze the etiopathogenic role of genetic polymorphisms and serum levels of surfactant protein-D (SP-D) in primary Sjögren syndrome (pSS).Methods.We analyzed 210 consecutive patients with pSS.SFTPDgenotyping (M11T polymorphism rs721917) was analyzed by sequence-based typing and serum SP-D by ELISA.Results.Thirty-two patients (15%) had the Thr11/Thr11 genotype, 80 (38%) the Met11/Met11 genotype, and 96 (46%) the Met11/Thr11 genotype; 2 patients could not be genotyped. Patients carrying the Thr11/Thr11 genotype had a higher prevalence of renal involvement (13% vs 1% and 4% in comparison with patients carrying the other genotypes, p = 0.014). Serum SP-D levels were analyzed in 119 patients (mean 733.94 ± 49.88 ng/ml). No significant association was found between serum SP-D levels and the SP-D genotypes. Higher mean values of serum SP-D were observed in patients with severe scintigraphic involvement (851.10 ± 685.69 vs 636.07 ± 315.93 ng/ml, p = 0.038), interstitial pulmonary disease (1053.60 ± 852.03 vs 700.36 ± 479.33 ng/ml, p = 0.029), renal involvement (1880.64 ± 1842.79 vs 716.42 ± 488.01 ng/ml, p = 0.002), leukopenia (899.83 ± 661.71 vs 673.13 ± 465.88 ng/ml, p = 0.038), positive anti-Ro/SS-A (927.26 ± 731.29 vs 642.75 ± 377.23 ng/ml, p = 0.006), and positive anti-La/SS-B (933.28 ± 689.63 vs 650.41 ± 428.14 ng/ml, p = 0.007), while lower mean values of serum SP-D were observed in patients with bronchiectasis (489.49 vs 788.81 ng/ml, p = 0.019).Conclusion.In pSS, high SP-D levels were found in patients with severe glandular involvement, hypergammaglobulinemia, leukopenia, extraglandular manifestations, and positive anti-Ro/La antibodies. The specific association between SP-D levels and pulmonary and renal involvements may have pathophysiological implications.

Clinically Significant and Biopsy-Documented Renal Involvement in Primary Sjogren Syndrome

Medicine ◽  
2000 ◽  
Vol 79 (4) ◽  
pp. 241-249 ◽  
Author(s):  
Andreas Goules ◽  
Stavroula Masouridi ◽  
Athanasios G. Tzioufas ◽  
John P. A. Ioannidis ◽  
Fotini N. Skopouli ◽  
...  
Keyword(s):  
Renal Involvement ◽  
Sjögren Syndrome ◽  
Sjogren Syndrome ◽  
Primary Sjögren Syndrome ◽  
Clinically Significant

scholarly journals Primary Sjogren Syndrome: Focus on Innate Immune Cells and Inflammation

Vaccines ◽  
2020 ◽  
Vol 8 (2) ◽  
pp. 272
Author(s):  
Chiara Rizzo ◽  
Giulia Grasso ◽  
Giulia Maria Destro Castaniti ◽  
Francesco Ciccia ◽  
Giuliana Guggino
Keyword(s):  
Sjögren Syndrome ◽  
Innate Immune ◽  
Lymphoid Cells ◽  
Sjogren Syndrome ◽  
Innate Immune Cells ◽  
Complex Interplay ◽  
Innate And Adaptive Immunity ◽  
Primary Sjögren Syndrome ◽  
Long Time

Primary Sjogren Syndrome (pSS) is a complex, multifactorial rheumatic disease that mainly targets salivary and lacrimal glands, inducing epithelitis. The cause behind the autoimmunity outbreak in pSS is still elusive; however, it seems related to an aberrant reaction to exogenous triggers such as viruses, combined with individual genetic pre-disposition. For a long time, autoantibodies were considered as the hallmarks of this disease; however, more recently the complex interplay between innate and adaptive immunity as well as the consequent inflammatory process have emerged as the main mechanisms of pSS pathogenesis. The present review will focus on innate cells and on the principal mechanisms of inflammation connected. In the first part, an overview of innate cells involved in pSS pathogenesis is provided, stressing in particular the role of Innate Lymphoid Cells (ILCs). Subsequently we have highlighted the main inflammatory pathways, including intra- and extra-cellular players. A better knowledge of such processes could determine the detection of new therapeutic targets that are a major need for pSS.

Primary Sjögren syndrome in a 2-year-old patient: role of the dentist in diagnosis and dental management with a 6-year follow-up

2011 ◽  
Vol 21 (6) ◽  
pp. 471-475 ◽  
Author(s):  
MARCIO AUGUSTO De OLIVEIRA ◽  
NATHALIE PEPE MEDEIROS De REZENDE ◽  
CÉLIA MÁRCIA FERNANDES MAIA ◽  
MARINA GALLOTTINI
Keyword(s):  
Sjögren Syndrome ◽  
Sjogren Syndrome ◽  
Patient Role ◽  
Primary Sjögren Syndrome ◽  
Dental Management

The Interleukin 33/ST2 Axis in Patients with Primary Sjögren Syndrome: Expression in Serum and Salivary Glands, and the Clinical Association

2014 ◽  
Vol 42 (2) ◽  
pp. 264-271 ◽  
Author(s):  
Seung Min Jung ◽  
Jaeseon Lee ◽  
Seung Ye Baek ◽  
Jae Ho Lee ◽  
Jennifer Lee ◽  
...  
Keyword(s):  
Salivary Glands ◽  
Activity Index ◽  
Disease Activity Index ◽  
Serum Levels ◽  
Interferon Γ ◽  
Sjögren Syndrome ◽  
Epithelial Cell Line ◽  
Sjogren Syndrome ◽  
Interleukin 33 ◽  
Primary Sjögren Syndrome

Objective.To evaluate the expression of interleukin 33 (IL-33) and its receptor in sera and salivary tissues of patients with primary Sjögren syndrome (pSS), and to investigate the association with clinical profiles.Methods.Serum IL-33 and soluble ST2 (sST2) of 55 patients with pSS and 48 controls were determined by ELISA and assessed for clinical correlation. The expression of IL-33/ST2 in salivary tissues was investigated by immunohistochemical staining and was further characterized by confocal microscopy. We also measured IL-33 production in salivary glandular epithelial cells by proinflammatory stimuli.Results.Serum levels of IL-33 and sST2 were higher in patients with pSS compared to those in controls (p = 0.018 and p < 0.0001, respectively). Among patients with pSS, sST2 concentration was associated with thrombocytopenia (p = 0.029) and correlated with disease duration (p = 0.013) and the European League Against Rheumatism Sjögren Syndrome Disease Activity Index (p = 0.042). The expression of IL-33 and ST2 was elevated in salivary glands of patients with pSS with grade 2 inflammation, and diminished in advanced inflammation. In patients with pSS, IL-33 was mainly observed in epithelial and endothelial cells of glandular tissue. The production of IL-33 mRNA by salivary gland epithelial cell line increased under stimulation with interferon-γ.Conclusion.The expression of IL-33 and its receptor was elevated in sera and salivary tissues of patients with pSS. These results suggest that the IL-33/ST2 axis might have a role in the pathogenesis of pSS.

scholarly journals Association of Smoking and Obesity on the Risk of Developing Primary Sjögren Syndrome: A Population-based Cohort Study

2019 ◽  
Vol 46 (7) ◽  
pp. 727-730 ◽  
Author(s):  
Luisa Servioli ◽  
Gabriel Maciel ◽  
Carlotta Nannini ◽  
Cynthia S. Crowson ◽  
Eric L. Matteson ◽  
...  
Keyword(s):  
Smoking Status ◽  
Population Based ◽  
Case Control ◽  
Sjögren Syndrome ◽  
Sjogren Syndrome ◽  
Olmsted County ◽  
Population Based Study ◽  
Primary Sjögren Syndrome ◽  
Never Smokers

Objective.To explore the role of smoking and obesity in primary Sjögren syndrome (pSS).Methods.Olmsted County (Minnesota, USA) residents (n = 106) diagnosed with pSS from 2000 to 2015 were compared to 3 controls without pSS and matched for age and sex who were randomly selected from Olmsted County residents.Results.Current smokers were less likely to be pSS cases (OR 0.34, 95% CI 0.14–0.85), while there was no association between former smoking and case/control status (OR 1.27, 95% CI 0.80–2.03) compared to never smokers. Smoking status was not associated with antinuclear antibody, anti-SSA, anti-SSB, or rheumatoid factor positivity (p > 0.05). OR for obesity was 0.79 (95% CI 0.48–1.30).Conclusion.In this population-based study, current smoking was inversely associated with case/control status, while body mass index lacked any association.

Biopsy-proven renal involvement and prognosis in 13 hispanic patients with primary Sjögren syndrome

2018 ◽  
Vol 150 (2) ◽  
pp. 43-48 ◽  
Author(s):  
Diego Luis Carrillo-Pérez ◽  
Javier Tejeda-Maldonado ◽  
Carlos Garza-García ◽  
Virgilia Soto-Abraham ◽  
Gabriela Hernández-Molina ◽  
...  
Keyword(s):  
Renal Involvement ◽  
Sjögren Syndrome ◽  
Sjogren Syndrome ◽  
Primary Sjögren Syndrome ◽  
Hispanic Patients
Sign in / Sign up

Export Citation Format

Share Document